We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+3.66%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.51B
AUM Growth
-$1.07B
Cap. Flow
-$907M
Cap. Flow %
-12.08%
Top 10 Hldgs %
65.31%
Holding
49
New
3
Increased
11
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$36.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$31.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26.4M
4
MRUS
Merus
MRUS
+$22.6M
5
SLNO
Soleno Therapeutics
SLNO
+$19.8M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$294M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$229M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$173M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$113M
5
MGNX icon
MacroGenics
MGNX
+$90.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.9B
$911M 12.13%
2,858,888
– –
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.4B
$576M 7.67%
2,055,555
+111,111
+6% +$26.4M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.6B
$572M 7.62%
4,196,661
+229,995
+6% +$31.3M
ARGX icon
4
argenx
ARGX
$54.9B
$533M 7.09%
1,238,467
– –
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.64B
$474M 6.31%
3,000,000
-1,344,444
-31% -$173M
KRYS icon
6
Krystal Biotech
KRYS
$10.6B
$447M 5.95%
2,433,000
-122,555
-5% -$20.6M
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$426M 5.68%
11,111,111
– –
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.9B
$375M 5%
4,557,416
+192,416
+4% +$16M
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$308M 4.11%
7,539,547
-16,008
-0.2% -$667K
XBI icon
10
State Street SPDR S&P Biotech ETF
XBI
$9.97B
$281M 3.75%
3,035,000
-1,265,000
-29% -$113M
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$272M 3.62%
27,400,000
– –
RNAM
12
DELISTED
Avidity Biosciences
RNAM
$266M 3.54%
6,505,000
+680,000
+12% +$19.5M
ARWR icon
13
Arrowhead Research
ARWR
$11.9B
$231M 3.08%
8,888,888
+333,333
+4% +$8.19M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.16B
$221M 2.94%
5,666,666
– –
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$205M 2.74%
3,000,000
+525,000
+21% +$36.4M
VERA icon
16
Vera Therapeutics
VERA
$2.31B
$156M 2.08%
4,309,590
-955,410
-18% -$37.9M
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.58B
$122M 1.62%
2,770,000
+190,000
+7% +$8.05M
KYMR icon
18
Kymera Therapeutics
KYMR
$8.6B
$116M 1.55%
3,888,888
– –
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$38.1B
$97.2M 1.29%
400,000
+100,000
+33% +$15.8M
IOVA icon
20
Iovance Biotherapeutics
IOVA
$2.03B
$93.8M 1.25%
11,700,000
– –
SLNO
21
DELISTED
Soleno Therapeutics
SLNO
$85.3M 1.14%
2,091,666
+466,666
+29% +$19.8M
MRUS
22
DELISTED
Merus
MRUS
$80.2M 1.07%
1,355,000
+466,112
+52% +$22.6M
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.67B
$79.8M 1.06%
3,888,437
-333,785
-8% -$6.99M
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$2.43B
$77.7M 1.03%
12,570,000
-480,000
-4% -$2.65M
KURA icon
25
Kura Oncology
KURA
$785M
$72.9M 0.97%
3,541,505
-308,495
-8% -$6.34M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Avoro Capital Advisors held 49 positions worth $7.51B, down 12% from $8.57B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Avoro Capital Advisors withdrew a net $907M in Q2 2024, closing 8 positions and reducing 9 holdings. Its most notable exit was Viking Therapeutics, an estimated $294M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Bicycle Therapeutics worth $14.2M.

  • Avoro Capital Advisors's largest Q2 2024 buy was Bicycle Therapeutics: 700,000 shares worth $14.2M.
  • Avoro Capital Advisors added most to Intra-Cellular Therapies Inc. in Q2 2024, an estimated $36.4M increase.
  • Avoro Capital Advisors's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $173M.
  • Avoro Capital Advisors fully exited Viking Therapeutics in Q2 2024, selling an estimated $294M.
  • Avoro Capital Advisors's ten largest holdings make up 65% of its $7.51B portfolio in Q2 2024.
  • Avoro Capital Advisors opened 3 new positions and closed 8 in Q2 2024.
  • Avoro Capital Advisors's portfolio value fell 12% quarter-over-quarter to $7.51B.

Based on Avoro Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.